These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23073299)

  • 1. Threshold serum concentrations of tumour necrosis factor alpha (TNFα) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM).
    Zorena K; Kula M; Malinowska E; Raczyńska D; Myśliwiec M; Raczyńska K
    Hum Immunol; 2013 Jan; 74(1):75-81. PubMed ID: 23073299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
    Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
    Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate: possible role of AGE peptide-associated endothelial dysfunction.
    Schalkwijk CG; Ter Wee PM; Stehouwer CD
    Ann N Y Acad Sci; 2005 Jun; 1043():662-70. PubMed ID: 16037290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus.
    Farhan SS; Hussain SA
    Diabetes Metab Syndr; 2019; 13(4):2457-2461. PubMed ID: 31405660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.
    Yu Y; Hanssen KF; Kalyanaraman V; Chirindel A; Jenkins AJ; Nankervis AJ; Torjesen PA; Scholz H; Henriksen T; Lorentzen B; Garg SK; Menard MK; Hammad SM; Scardo JA; Stanley JR; Wu M; Basu A; Aston CE; Lyons TJ
    BJOG; 2012 Nov; 119(12):1512-20. PubMed ID: 22900949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications.
    Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Nakatani Y; Ohtoshi K; Hayaishi-Okano R; Kosugi K; Hori M; Yamasaki Y
    Diabetes Care; 2005 Nov; 28(11):2716-21. PubMed ID: 16249545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interleukin 12 as an anti-angiogenic mediator in type 1 diabetic children].
    Zorena K; Myśliwska J; Myśliwiec M; Balcerska A; Lipowski P; Raczyńska K
    Pediatr Endocrinol Diabetes Metab; 2007; 13(1):27-31. PubMed ID: 17493403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between vascular endothelial growth factor and hypertension in children and adolescents type I diabetes mellitus.
    Zorena K; Myśliwska J; Myśliwiec M; Rybarczyk-Kapturska K; Malinowska E; Wiśniewski P; Raczyńska K
    J Hum Hypertens; 2010 Nov; 24(11):755-62. PubMed ID: 20164848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.
    Aso Y; Inukai T; Tayama K; Takemura Y
    Acta Diabetol; 2000; 37(2):87-92. PubMed ID: 11194933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum advanced glycation end-products and receptors as prognostic biomarkers in diabetics undergoing coronary artery stent implantation.
    Shen Y; Pu LJ; Lu L; Zhang Q; Zhang RY; Shen WF
    Can J Cardiol; 2012; 28(6):737-43. PubMed ID: 23073352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.
    Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Sato A; Imaizumi T
    Diabetes Metab Res Rev; 2007 Jul; 23(5):368-71. PubMed ID: 17024691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications.
    Chiarelli F; Spagnoli A; Basciani F; Tumini S; Mezzetti A; Cipollone F; Cuccurullo F; Morgese G; Verrotti A
    Diabet Med; 2000 Sep; 17(9):650-6. PubMed ID: 11051284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
    Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The assessment of the correlation between vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-alpha), interleukin 6 (IL-6), glycaemic control (HbA1c) and the development of the diabetic retinopathy in children with diabetes mellitus type 1].
    Myśliwiec M; Balcerska A; Zorena K; Myśliwska J; Lipowski P; Raczyńska K
    Klin Oczna; 2007; 109(4-6):150-4. PubMed ID: 17725274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
    Abdel-Azeez HA; El-Okely AM
    Egypt J Immunol; 2009; 16(1):95-106. PubMed ID: 20726326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.
    Berg TJ; Snorgaard O; Faber J; Torjesen PA; Hildebrandt P; Mehlsen J; Hanssen KF
    Diabetes Care; 1999 Jul; 22(7):1186-90. PubMed ID: 10388987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end products in adolescents and young adults with diabetic angiopathy.
    Chiarelli F; Catino M; Tumini S; Cipollone F; Mezzetti A; Vanelli M; Verrotti A
    Pediatr Nephrol; 2000 Aug; 14(8-9):841-6. PubMed ID: 10955941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications.
    Sherif EM; El Maksood AAA; Youssef OI; Salah El-Din NY; Khater OKM
    J Diabetes Complications; 2019 Sep; 33(9):628-633. PubMed ID: 31301955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications.
    Adly AAM; Ismail EA; Tawfik LM; Ebeid FSE; Hassan AAS
    Cytokine; 2015 Dec; 76(2):156-162. PubMed ID: 26142824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of growth factor levels in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy].
    Peczyńska J; Urban M; Urban B; Głowińska B; Florys B
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(1):41-8. PubMed ID: 15355738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.